Jump to content
Linus

Opinion: The New Ketamine-Based Antidepressant Is a Rip-Off

Recommended Posts

Linus

It was no better than placebo in two of the three short-term Phase-III studies submitted to the FDA for approval.

 

But the biggest problem at hand is not the drug itself. It’s the fact that instead of representing a revolution in mental health treatment, as it has been touted to do, esketamine is not a breakthrough at all. It’s just a way for pharmaceutical company Johnson & Johnson to make a significant profit off gullible insurance companies and vulnerable patients.

 

https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off?fbclid=IwAR2HdQjDaaGdn2rvIwtPdllr0czgUYm8ES8fyX6NcyQAiZiqLDemZIxcwjk

Share this post


Link to post
Share on other sites
Rosetta

Not to mention the negative effects and downsides which undoubtedly have been hidden, downplayed and outright denied.  At $900 a dose and $7,000 for the first month of treatment let's hope very few people have the "opportunity" to be "helped" by this new drug.  After what has happened with fosamax, Vioxxx, oxycontin and all the benzos as well as the ADs, I don't trust the pharmaceutical companies with regard to anything at all. 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...